2 Top Nanotech Stocks to Buy for the Second Half of 2021

NYSE: TMO | Thermo Fisher Scientific Inc. News, Ratings, and Charts

TMO – The demand for nanotechnology is growing with its numerous applications in industries from healthcare to agriculture. Because many countries and companies are increasingly focusing on nanoscience and nanotechnology innovations to drive some of the world’s biggest breakthroughs, the industry holds solid growth prospects. So, we believe nanotech stocks Thermo Fisher Scientific (TMO) and Onto Innovations (ONTO) are good bets now. Read on.

Nanotechnology is emerging rapidly, outpacing other technologies at a breakneck speed, with potential uses in various sectors, including computer and electronics, healthcare, cosmetics, textile, energy, and agriculture, to mention a few. Interestingly, its growing use in the healthcare sector has enabled researchers to develop more innovative and effective drugs.

Rapid developments in healthcare technology and growing government spending on biotechnology and pharmaceutical R&D are anticipated to drive the nanotech sector’s growth. The global nanotechnology market is expected to reach $126.8 billion by 2027, growing at a 12.9% CAGR.

Given the accelerating growth of the nanotechnology market, we think it may be prudent to bet on fundamentally strong nanotech companies Thermo Fisher Scientific Inc. (TMO) and Onto Innovations Inc. (ONTO), which have the potential to deliver  huge returns to investors in the coming months.

Thermo Fisher Scientific Inc. (TMO)

TMO provides scientific instrumentation and software services. It develops and distributes various products under the brand names Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services are the four segments through which the Waltham, Mass., company operates.

This month, TMO  opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, California, to meet the rapidly increasing demand for plasmid DNA-based therapies and mRNA-based vaccines. Because  plasmid DNA is being used increasingly as a therapeutic option in gene treatments and vaccinations, the company is well-positioned to see substantial growth in revenues in the coming months.

During the second quarter, ended July 3, 2021, TMO’s revenue increased 34.1% year-over-year to $9.27 billion. The company’s operating income increased 55.5% year-over-year to $2.16 billion over this period. Its net income increased 58.1% year-over-year to $1.83 billion, while its EPS grew 59% from the prior-year quarter to $4.61.

A  $22.12  consensus EPS estimate for the current year represents a 13.1% improvement year-over-year. The $35.66 billion consensus revenue estimate  for 2021 represents a 10.7% increase from the same period last year. The stock has gained 29.7% over the past year and 13.4% year-to-date.

TMO’s POWR Ratings reflect this promising outlook. The company has an overall B rating, which translates to Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

TMO is also graded  an A  for Growth. In addition, , within the Medical – Diagnostics/Research industry, it is ranked #9 of 55 stocks.

To see more of TMO’s component grades, click here.

Click here to checkout our Healthcare Sector Report for 2021

Onto Innovation Inc. (ONTO)

ONTO is a manufacturer of semiconductor equipment and software technologies. The Flanders, N.J.-based company provides a range of technologies for wafer production, front-end process management, and advanced semiconductor packaging lithography. In addition, the company offers overlay metrology for controlling lithography and etch operations in the compound semiconductor sector.

During the first quarter, ended March 27, 2021, ONTO’s non-GAAP revenue increased 21% year-over-year to $169.28 million. The company’s non-GAAP operating income increased 82.6% year-over-year to $41.87 million. Its non- GAAP net income increased 84.1% year-over-year to $36.34 million, while its non-GAAP EPS increased 87.2% year-over-year to $0.73 over this period.

ONTO is expected to witness 29%  revenue growth for the current year. Its EPS is estimated to increase 64.8% year-over-year to $3.18 in 2021. Over the past year, ONTO’s stock has gained 91.1%. Furthermore, it has gained 41% year-to-date.

ONTO’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which equates to Buy in our POWR Ratings system. The stock also has a B grade for Growth, Momentum, and Quality. In the B-rated Semiconductor & Wireless Chip same industry, it is ranked #35 of 99 stocks.

In total, we rate ONTO on eight different levels. Beyond what we’ve stated above, we have also given ONTO grades for Stability, Sentiment, and Value. Get all the ONTO ratings here.

Click here to checkout our Semiconductor Industry Report for 2021


TMO shares were trading at $532.31 per share on Thursday afternoon, up $4.04 (+0.76%). Year-to-date, TMO has gained 14.41%, versus a 18.83% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TMOGet RatingGet RatingGet Rating
ONTOGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

:  |  News, Ratings, and Charts

3 Stocks that Are Thriving in an Inflationary Environment

Inflation is one of the biggest threats facing the economy. One profitable strategy during this period of high inflation is to focus on stocks that have pricing power, as these companies’ margins will continue to expand. In contrast, stocks without pricing power are likely to underperform as margin compression erodes EPS. Therefore, investors should consider buying these 3 stocks that are thriving in this inflationary environment: Olin (OLN), Nucor (NUE), and Chemours (CC).

:  |  News, Ratings, and Charts

Is the Bear Market Here?

We are witnessing the nastiest stock market (SPY) correction since Covid first came on the scene. That has some pondering if the next bear market is upon us. 40 year veteran investor Steve Reitmeister gives his clear eyed view on the market outlook and trading plan in this timely commentary. Get the full story below...

:  |  News, Ratings, and Charts

4 Best Value Stocks to Buy in January

In times of high inflation, value stocks tend to outperform growth stocks and have done so over the past year. Amid the rising inflationary pressure and looming interest rate hikes, fundamentally sound value stocks ArcelorMittal (MT), Covestro (COVTY), KT Corporation (KT), and Nature’s Sunshine (NATR) could be solid bets.

:  |  News, Ratings, and Charts

Is the Bear Market Here?

We are witnessing the nastiest stock market (SPY) correction since Covid first came on the scene. That has some pondering if the next bear market is upon us. 40 year veteran investor Steve Reitmeister gives his clear eyed view on the market outlook and trading plan in this timely commentary. Get the full story below...

Read More Stories

More Thermo Fisher Scientific Inc. (TMO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TMO News